Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer


TAŞKIN S., GÜNGÖR M., Ortac F., Oztuna D.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.288, no.6, pp.1399-1403, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 288 Issue: 6
  • Publication Date: 2013
  • Doi Number: 10.1007/s00404-013-2924-7
  • Journal Name: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.1399-1403
  • Keywords: Neoadjuvant chemotherapy, Ovarian cancer, Optimal cytoreduction, Survival, CARCINOMA, DEBULKING, DISEASE
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance